Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence

In English

Författare

  • Nadia Stefanova
  • Martin Kollensperger
  • Monika Hainzer
  • Angela Cenci Nilsson
  • Werner Poewe
  • Gregor Karl Wenning

Summary, in English

Levodopa is generally regarded the first choice therapy for parkinsonism associated with multiple system atrophy (MSA-P). However, MSA-P patients often show a poor or unsustained levodopa response which inflicts high dose therapy. This is generally attributed to progressive striatal degeneration with loss of dopamine receptors. Experimental evidence suggests that dopaminergic stimulation may accelerate the striatal disease process in MSA, possibly by pro-oxidative mechanisms. Intact nigrostriatal dopamine release augments striatal lesion size in the unilateral nigral and striatal double lesion rat model of MSA-P. Further, neuronal vulnerability to exogenous oxidative stress is increased in a transgenic MSA mouse model with oligodendroglial alpha-synuclein inclusions. The aim of the present study was to analyze whether high dose levodopa delivery in the transgenic MSA model is associated with neurotoxicity exacerbated by the presence of oligodendroglial alpha-synuclein inclusion pathology. Control and transgenic MSA mice underwent pulsatile treatment with either vehicle, low or high dose levodopa for a period of 1 month. Behavioral and neuropathological indices failed to show evidence for neurotoxic effects of high-dose levodopa in this alpha-synuclein transgenic MSA model. These findings support the idea that high dose levodopa therapy in MSA is not detrimental to the underlying neuropathological process. (C) 2007 Movement Disorder Society.

Publiceringsår

2007

Språk

Engelska

Sidor

969-973

Publikation/Tidskrift/Serie

Movement Disorders

Volym

27

Issue

7

Dokumenttyp

Artikel i tidskrift

Förlag

John Wiley & Sons Inc.

Ämne

  • Neurology

Nyckelord

  • levodopa
  • neurodegeneration
  • glial cytoplasmic inclusions
  • alpha-synuclein
  • multiple system atrophy
  • transgenic mouse

Status

Published

Forskningsgrupp

  • Basal Ganglia Pathophysiology

ISBN/ISSN/Övrigt

  • ISSN: 0885-3185